Press "Enter" to skip to content

NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics – Business Wire

admin 0

NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics  Business Wire

NantKwest Inc. (Nasdaq:NK) announced today that its strategic partner Viracta Therapeutics presented updated clinical data on its HDAC inhibitor, nana.

“lymphoma cancer” – Google News

(Visited 5 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *